RTM receives marketing authorisation for Fludeoxyglucose (18F)

We are happy to announce that RTM has received marketing authorization for ¹⁸F-FDG of 17 July 2018.

Fludeoxyglucose (¹⁸F) RTM 200 MBq/ml, solution for injection will become commercially available in The Netherlands in October, with roll-out to Belgium and Germany planned in 2019.

Other news

RTM added as distributor NeuraCeq®

Exciting news! Life Molecular Imaging’s NeuraCeq® 300 MBq/ml solution for injection (florbetaben 18F...

First liver cancer patient treated with microspheres irradiated in TU Delft

Radboud Translational Medicine will perform the dispensing of below product. The production and dis...

First Patient Dosed in Phase II Study of TLX250-CDx in Triple-Negative Breast Cancer

The below product is manufactured at RTM First Patient Dosed in Phase II Study of TLX250-CDx in Tri...

Cooperation RTM-Alliance Medical

It is with great pleasure that we announce our cooperation with Alliance Medical Group (AMG) regardi...

News